Management of hepatitis C

Journal of Viral Hepatitis

Volumn 5, Issue 2, 1998, Pages 73-82

  Moussalli, J ^a   Opolon, P ^a   Poynard, T ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Hepatitis C virus; Interferon; Ribavirin; Therapy

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ANTIVIRAL ACTIVITY; CANCER PREVENTION; CHRONIC HEPATITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; HEPATITIS C; HUMAN; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER FIBROSIS; PRIORITY JOURNAL; REVIEW;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; RIBAVIRIN;

EID: 0031829694     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1998.00086.x     Document Type: Review

References (64)

1. Hoofnagle JH. Mullen KD, Brian Jones D et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha Interferon. N Engl J Med 1986; 315: 1575-1578.
2. Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology 1996; 23: 909-916.
3. Peters M. Mechanism of action of interferons. Semin Liver Dis 1989; 9: 235-239.
4. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995; 21: 1003-1010.
5. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A double-blind placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510.
6. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-1506.
7. Marcellin P, Boyer N, Giostra E et al. Recombinant human alfa interferon in patients with chronic non-A non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-397.
8. Causse X, Godinot H, Chevallier M et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A non-B hepatitis. Gastroenterology 1991; 101: 497-502.
9. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for chronic non-A non-B hepatitis. A meta-analysis of randomized controlled trials. J Hepatol 1991; 13: 192-199.
10. Marcellin P, Pouteau M, Martinot-Peignoux M et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995; 109: 156-165.
11. Saez-Royuela F, Porres JC, Moreno A et al. High doses of recombinant alfa interferon or gamma interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1991; 13: 327-331.
12. Hakozaki Y, Shirahama T, Katou M et al. A controlled study to determine the optimal dose regimen of interferon alfa 2b in chronic hepatitis C. Am J Gastroenterol 1995; 90: 1246-1249.
13. Poterucha JJ, Gossard JB, Gross JR et al. High dose interferon alfa 2b for patients with chronic hepatitis C who have failed standard treatment. Gastroenterology 1996; 110: A1298 (abstr).
14. Chemello L, Bonetti P, Cavalletto L et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-706.
15. Shiratori Y, Yokosuka O, Imazeki F et al. Viral eradication rate is proportional to the total doses of Interferon; 'Tokyo-China' hepatitis C multicentric, randomized and prospective study. Gastroenterology 1996; 110: A1324 (abstr).
16. Heathcote J, Keefe E, Lee S et al. Retreatment of chronic HCV infection with a higher dose of consensus Interferon produces sustained responses in nonresponders and relapsers. Gastroenterology 1997; 112: A1280 (abstr).
17. Lam NP. Rapid HCV clearance with high induction interferon doses is important for sustained response. Gastroenterology 1997; 112: A1312 (abstr).
18. Reichard O, Foberg U, Fryden A et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon alfa 2b for 60 weeks. Hepatology 1994; 19: 280-285.
19. Poynard T, Bedossa P, Chevallier M et al. A comparison of three interferon alfa 2b regimens for long term treatment of chronic non-A non-B hepatitis. N Engl J Med 1995; 332: 1457-1462.
20. Angelini G, Sgarbi D, Colombari R et al. Alpha-interferon treatment of chronic hepatitis C: a controlled, multicentre, prospective study. Digestion 1995; 56: 199-203.
21. Kasahara A, Hayashi N, Hiramatsu N et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995; 21: 291-297.
22. Marcellin P, Pouteau M, Boyer N, Castelnau C, Erlinger S, Benhamou JP. Retreatment with recombinant interferon-alpha in patients with chronic hepatitis C. J Infect Dis 1993; 167: 780-781.
23. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789.
24. Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877-883.
25. Shindo M, Di Bisceglie A, Cheung L et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700-704.
26. Lau J, Mizokami M, Ohno T, Diamond D, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferon-alfa in chronic hepatitis C. Lancet 1993; 342: 1208-1209.
27. Sarraco G, Rosina F, Abate ML et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon alfa 2b. Hepatology 1993; 18: 1300-1305.
28. Reichard O, Glaumann H, Fryden A et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995; 21: 918-922.
29. Lee WM. Reddy KR, Van Leuwen DJ et al. Undetectable HCV RNA concentrations at early time points predict sustained virological responses after treatment with consensus Interferon. Gastroenterology 1997; 112: A1317 (abstr).
30. Hutchinson JG, Martinet M, Perillo R et al. Kinetics of changes in serum HCV RNA during Interferon therapy in patients with chronic hepatitis C infection. Gastroenterology 1997; 112: A1330 (abstr).
31. Romeo R, Pol S, Berthelot P, Brechet C. Eradication of hepatitis C virus RNA after alfa-interferon therapy. Ann Intern Med 1994; 121: 276-277.
32. Balart LA, Perillo R, Roddenberry J et al. Hepatitis C RNA in liver of chronic hepatitis patients before and after interferon alfa treatment. Gastroenterology 1993; 104: 1472-1477.
33. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832.
34. Manabe N, Chevallier M, Chossegros P et al. Interferon-alfa 2b therapy reduces liver fibrosis in chronic non-A non-B hepatitis: a quantitative histological evaluation. Hepatology 1993; 18: 1344-1349.
35. Craig JR, Bain VG, Ehrinpreis M et al. Liver histology improves in both cirrhotic and non cirrhotic patients with chronic HCV infection following consensus Interferon therapy. Gastroenterology 1997; 112: A1248 (abstr).
36. Jensen D, Shafritz D, Craig JR et al. Nonresponders to CIFN show clinically relevant improvements in liver histology. Gastroenterology 1997; 112: A1294 (abstr).
37. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997; 26: 1187-1199.
38. Degos F, Daurat V, Gayno S et al. A randomized comparison of standard and reinforced schedules of alfa interferon in chronic hepatitis C. Hepatology 1996; 24: 275A (abstr).
39. Accogli E, Mazzella G, Somli S et al. Alpha interferon prevents hepatocellular carcinoma in responders with HCV-associated hepatic cirrhosis. Gastroenterology 1997; 112: A1206 (abstr).
40. Nishiguchi S, Kuroki T, Nakatani S et al. Randomized trial of effects of interferon alfa on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
41. Jouet P, Roudot-Thoraval F, Dhumeaux D et al. Comparative efficacy of interferon alfa in cirrhotic and non-cirrhotic patients with non-A non-B, C hepatitis. Gastroenterology 1994; 106: 686-690.
42. Davis G, Beck JR, Farrell G, Poynard T. Prolonged course versus 6 months of interferon alfa or no treatment in patients with histologically mild chronic hepatitis C: a decision analysis. Gastroenterology 1997; 112: A1252 (abstr).
43. Lau JYN, Davis GL, Kniffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-1504.
44. Magrin S, Craxi A, Fabiano C et al. Hepatitis C viremia in chronic liver disease: relationship to interferon alfa or corticosteroid treatment. Hepatology 1994; 19: 273-279.
45. Tsubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon-alfa therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-1094.
46. Martinot-Peignoux M, Marcellin P, Pouteau M et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-1056.
47. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
48. Sakuma I, Enomoto N, Asahina Y et al. Differential effect of interferon therapy on hepatitis C virus 1B quasispecies in the non-structural 5A gene. Gastroenterology 1997; 112: A1371 (abstr).
49. Chung RT, Monto A, Dienstag JL, Kaplan LM. NS5A mutations do not predict response to interferon in American patients infected with genotype 1 hepatitis C virus. Gastroenterology 1997; 112: A1244 (abstr).
50. Browne MJ. Mechanism and specificity of action of Ribavirin. Antimicrob Agents Chemother 1978; 15: 747-753.
51. Goswami BB, Borek E, Sharma OK. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem Biophys Res Commun 1979; 89: 830-836.
52. Patterson JL, Fernandez-Larson R. Molecular action of ribavirin. Rev Infect Dis 1990; 12: 1132-1146.
53. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058-1061.
54. Di Bisceglie A, Shindo M, Fong TL et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649-654.
55. Bodenhaimer HC, Lindsay KL, Davis GL et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1994; 20: 207A (abstr).
56. Di Bisceglie AM, Conjeevaram HS, Fried MW et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897-903.
57. Brouwer JT, Nevens F, Michielsen P et al. What options are left when hepatitis C does not respond to interferon? Placebo-controlled Benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferon. J Hepatol 1994; 21: S17 (abstr).
58. Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavirin and interferon beta for treatment of chronic hepatitis C. Gastroenterology 1993; 105: 507-512.
59. Chemello L, Cavaletto L, Bernardinello E et al. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23 (suppl 2): 8-12.
60. Lai MY, Kao JH, Yang PM et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-1312.
61. Weiland O, Schvarcz R, Yun Z, Sonneborg A. IFN relapsers and nonresponders: Scandinavian experience. In: Perspectives on a new paradigm: combination antiviral therapy in chronic hepatitis C. Proceedings of the European Association for the Study of the Liver; 1995: 441-450.
62. Schalm SW, Hansen BE, Chemello L et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997; 26: 961-966.
63. Thevenot T, Mathurin P, Moussalli J et al. Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin. J Viral Hep 1997; 4: 243-253.
64. Saito T, Shinzawa H, Kuboki M et al. A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol 1994; 89: 681-686.